NCT01147081View on ClinicalTrials.gov

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

BEGRIVAC

126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)

Trial Locations (3)

18057

Universität Rostock/Medizinische Fakultät, Ernst-Heydemann Str. 6

20359

Hamburg

39120

Magdeburg

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY